Q-omics provides the consensus-scored PDCD4 profile across patient tissues and cancer cell-line models. PDCD4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PDCD4 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, PDCD4 RNA expression shows 20,085 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, COAD, and UVM as cancer lineages where PDCD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDCD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDCD4 survival associations across molecular data types. PDCD4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDCD4 RNA expression–survival associations across cancer types. High PDCD4 expression shows unfavorable associations in KIRP, but favorable associations in BRCA, KIRC, MESO, SCLC and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PDCD4 RNA expression.
This table summarizes PDCD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PDCD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDCD4 shows lower tumor expression in COAD, UCEC, HNSC, BLCA and LUAD and higher tumor expression in LIHC. The COAD box plot shows higher PDCD4 RNA expression in normal versus tumor tissue (log2 FC = −2.634, t-test p < 0.001).
This table shows molecular features associated with PDCD4 in patient tissues and cancer cell lines. In patient samples, PDCD4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDCD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BREAST.
